ABCB1 G2677T

Conclusions The homozygous mutant TT genotypes (C1236T and C3435T) and heterozygous CT genotypes (C1236T) showed significant association to chemo-induced toxicity (hematological toxicity, nausea, vomiting, alopecia) in patients underwent anthracycline and taxane. Hence, these SNPs could serve as predictive markers to mitigate chemotherapy's adverse effects and optimize treatment to reduce the grade of toxicity and improves patients quality of life.

As the findings indicate, lung cancer and control groups demonstrate significantly different patterns of -129/1236/2677/3435 haplotype distribution; T-T-T-T haplotype contributes to NSCLC susceptibility, and this effect is probably mainly dependent on C3435T. So far, similar studies were published in other populations.

A slight trend can be observed in subjects with mutated genotype of ABCB1 C3435T, C1236T and G2677T/A polymorphisms.CONCLUSIONSCLL treatment has a high rate of ADR, the main risk being bleeding. So far, polymorphisms in enzymes and transporters involved in the ibrutinib pathway have not been shown to affect the incidence of ADR in CLL patients, probably due to the small sample size of our study.In addition to increasing the sample size, steady-state plasma concentrations of ibrutinib will be measured in order to correlate drug levels with polymorphisms in the genes analyzed and the incidence of ADR.

However, they may not be the critical ones when it comes to risk or recovery assessment. Consequently, they may not be treated as reliable prognostic or predictive markers in breast cancer patients' evaluation, which supports the previous findings and current knowledge.

Indonesia breast cancer patients who underwent three cycles of chemotherapy demonstrated susceptibility to hematological toxicity by developing side effects such as anemia and neutropenia. However, no relationship was found between hematological toxicity and ABCB1 and GSTP1 polymorphisms.

The current study provides preliminary evidence of a significant association between variant TT genotype and increased B-ALL risk. Also, results suggest that ABCB1 3435TT genotype increases imatinib resistance in CML and influence therapeutic outcome in B-ALL.

We showed that in childhood B-ALL, the intracellular VCR levels in lymphoblasts affected treatment outcomes. The intracellular VCR level was independent of leukaemia subtype but dependent on host ABCB1 G2677T genotype.

Similarly, no significant association was observed in the stratification analyses by ethnicity and control source. In conclusion, this meta-analysis suggests that ABCB1 G2677T/A polymorphism is not associated with genetic susceptibility to breast cancer.